After years of research and clinical testing, we have developed non-invasive, accurate blood tests for early detection of cancer. By making cancer prevention routine, we enable everyone to take control of their own health. The more people take our breakthrough blood tests, the more lives we can save. Life over cancer.

Company

We are a liquid biopsy company focused on cancer screening with a proprietary technology for detecting precancer and cancer cells in a single blood sample. We have built a team of experts across multiple disciplines, including precancer and cancer cell capture and imaging, algorithm development, biostatistics, and development and commercialization of clinical grade tests.

Management

Atul Sharan

Chief Executive Officer

Rui Mei, PhD

Chief Scientific Officer

Dr Mana Javey MD, PhD

Medical Director

Drew Watson, PhD

Sr. VP of Clinical Studies & Biostatistics

Todd Whitson

Chief Commercial Officer

Atul Sharan

Chief Executive Officer

Akhil Saklecha, MD

Board Member

Amit Shah

Board Member

Stan Shih

Founder and Chairman, Acer, Board Observer

Yuchiro Morimoto

CEO, Silicon Valley Venture Fund, Board Member

David R. Gandara, MD

Oncologist and Professor of Medicine at the University of California at Davis School of Medicine

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center

Ashish Nimgaonkar, MD

Assistant Professor of Medicine Johns Hopkins; Associate Medical Director
CBID

Heinz Josef Lenz, MD

Professor of Medicine and Preventive Medicine, GI; Keck School of Medicine, USC

Mark Pegram, MD

Oncologist and Professor, Stanford; Director, Breast Cancer Oncology Program, Women’s Cancer Center

Mahul Amin, MD

Chair, Dept. of Pathology, College of Medicine Univ. of Tennessee Health Science Center;

UTHSC Gerwin Chair for Cancer Research

Dave Lawrence, MD

Advisor, Artiman Ventures; Former CEO & Chairman, Kaiser Foundation Health Plan and Hospitals

Atul Sharan

Chief Executive Officer

In 2012, as an Entrepreneur in Residence at a leading Silicon Valley Venture Firm, Artiman Ventures, Atul Sharan co-founded CellMax Life, applying semiconductor industry principles to a proprietary Circulating Tumor Cell (CTC) bio-mimetic CMx platform to develop affordable, clinically proven blood-tests for Early Cancer Detection and Treatment. He was motivated to start CellMax as two members of his family have been diagnosed with cancer – one of them was diagnosed with breast cancer within two weeks of receiving a conclusively negative mammogram. Atul is a veteran of the high-tech industry with experience as an engineer, serial entrepreneur, CEO and angel investor. He specializes in identifying unmet market needs and matching them with early-stage technologies to achieve dramatically better results than prevailing standards. He has done that successfully multiple times: AutoESL (acquired by Xilinx); ClearShape Technologies (acquired by Cadence), Numerical Technologies (Nasdaq IPO; acquired by Synopsys); Ambit Design (acquired by Cadence). Atul holds a BS in Engineering from IIT-India; MS in Engineering from UH, Texas and an MBA from UC-Berkeley.

Rui Mei, PhD

Chief Scientific Officer & VP of R&D

As Chief Scientific Officer at CellMax Life, Dr Mei leads a global team of R&D scientists, CLIA and CAP laboratory professionals, bioinformaticians and software engineers. She is responsible for the development of CellMax Life’s multi-biomarker platforms, including the precancer and cancer cell detection, next generation sequencing (NGS), methylation and protein expression platforms. Prior to joining CellMax Life, Dr Mei was Vice President of R&D and genomic service operations, and part of the founding team at Centrillion Biosciences, where she established that company's next-generation sequencing services for pharmaceutical companies, researchers and physicians. At Affymetrix, a pioneer in multi-biomarker analysis tools, Dr Mei led the development of multiple products for genotyping, re-sequencing, and gene expression analysis. She received her PhD in Biochemistry from the University of Michigan, Ann Arbor, and post-doctoral training in Nucleic Acid Enzymology at Stanford University. Dr Mei has published over 40 articles in peer-reviewed scientific journals and holds 20 patents.

Mana Javey, MD, PhD

Medical Director

Dr Javey is responsible for the regulatory approvals and accreditation of CellMax Life’s laboratories. She is also responsible for Medical and Scientific Affairs. Dr Javey is an authority on laboratory accreditation for circulating tumor cells and NGS. She led regulatory filings with the CMS (Centers for Medicare Services) and the College of America Pathologists (CAP), which resulted in successful CLIA accreditation of the CellMax Life laboratory in Sunnyvale, California, and CAP accreditation of the company’s labs in both Taipei, Taiwan and Sunnyvale, California. Dr Javey holds an MD and PhD in immunology and biochemistry. She did her pathology residency training at University of California, San Francisco, and a postdoctoral fellowship at Stanford University School of Medicine. She has won numerous institutional and national awards including the Dean’s Fellowship at Stanford and has co-authored several peer-reviewed publications.

Padma Sundar

VP of Strategy and Market Access

Padma Sundar is responsible for corporate strategy, market access and marketing at CellMax Life. She has over 20 years of experience commercializing and driving adoption of novel diagnostics. Prior to CellMax, Padma led product management and marketing for Guardant Health's liquid biopsy, leading to its adoption by 80% of oncologists in the United States. Padma also led product management at Roche Sequencing for their liquid biopsy tests, which have been launched in over 50 countries worldwide for cancer treatment selection and monitoring. Padma began her career at McKinsey & Company’s healthcare practice. She has an MBA-MPH from UC Berkeley and a Bachelors in Chemistry.

Drew Watson

Sr. VP of Clinical Studies & Biostatistics

Dr Watson is responsible for clinical studies at CellMax Life. He is a highly accomplished senior executive with over 30 years of success in biostatistics and computational biology at Invitae, Genomic Health, Incyte Genomics, and Chiron Corporation. At Genomic Health, he led the pivotal clinical trial for the molecular diagnostic, Oncotype DX for breast cancer recurrence risk assessment, leading to its coverage by the Centers of Medicare and Medicaid (CMS). He has published extensively in the area of biostatistics, oncology and genomics, and is a holder of multiple key U.S. patents in genomics, algorithm development, and personalized medicine. Dr Watson earned a B.S. in Statistics from California State University East Bay, an M.S. in Computational Statistics from Stanford University, an M.B.A. in Strategic Management from Golden State University, and a PhD in Biostatistics from University of California Los Angeles (UCLA).

Todd Whitson, Chief Commercial Officer

Todd Whitson

Chief Commercial Officer

Todd Whitson is responsible for test commercialization and global business development at CellMax Life. Todd has over 15 years of experience in healthcare as a commercial leader, building and accelerating growth for early stage diagnostic companies. Before joining CellMax Life, Todd had a number of leadership roles in the molecular diagnostic industry, most notably serving as vice president of commercial operations of Ariosa Diagnostics, a leader in blood-based non-invasive prenatal testing (NIPT). He helped grow the company from a startup with no revenue to generating $50 million in revenue within two years, which led to a $650 million acquisition by Roche. Prior to Ariosa, Todd also led sales at Genzyme Genetics, a leader in oncology and reproductive testing, helping to drive the success of the company to an acquisition by LabCorp for $950 million.

 

TOP